Pharmaceutical Supply Agreement (UAE)

A Pharmaceutical Supply Agreement in the United Arab Emirates is a commercial contract between a licensed pharmaceutical distributor or wholesaler and a licensed pharmacy or healthcare facility for the supply of MOHAP-registered medicines and pharmaceutical products on agreed pricing, delivery, and quality terms. The agreement governs the entire commercial supply relationship: which products are covered, how orders are placed and fulfilled, delivery and cold-chain requirements, pricing under the MOHAP price control framework, product recall obligations, and the termination conditions.

Pharmaceuticals in the UAE are regulated primarily by the Ministry of Health and Prevention (MOHAP) under Federal Law No. 4 of 1983 (the Drug Control Law) as amended. MOHAP maintains the UAE Drug Register, which lists all medicines authorised for sale in the UAE. Only registered medicines may be imported, stored, distributed, and dispensed. The Dubai Health Authority (DHA) additionally licenses and regulates pharmaceutical facilities and practitioners in Dubai, and the Department of Health Abu Dhabi (DOH) exercises the same function in Abu Dhabi. Controlled substances — narcotics and psychotropic substances — are subject to additional restrictions under Federal Law No. 14 of 1995 on the Countermeasures Against Narcotic Drugs and Psychotropic Substances.

Both the supplier and the buyer must hold the licences appropriate to their role. The supplier requires a pharmaceutical wholesale or distribution licence from MOHAP, or the relevant DHA or DOH licence. The buyer requires a pharmacy licence or healthcare facility licence from the relevant authority. A Pharmaceutical Supply Agreement between unlicensed parties or for the supply of unregistered products is unlawful and unenforceable.

The contractual framework rests on the UAE Civil Code (Federal Law No. 5 of 1985): Article 125 on contract formation, Article 246 on good-faith performance, Articles 282 and 389 on compensation for breach. The Commercial Transactions Law (Federal Decree-Law No. 50 of 2022) applies where both parties are merchants and governs commercial obligations, delivery, risk transfer, and late payment. Good Distribution Practice (GDP) standards issued by MOHAP impose quality and traceability obligations on both parties in the supply chain.

Value Added Tax under the VAT Law (Federal Decree-Law No. 8 of 2017), administered by the Federal Tax Authority (FTA), applies to pharmaceutical supply. Certain medicines and medical products are zero-rated under Cabinet Decision No. 52 of 2017, while other products are standard-rated at 5%. The agreement must address VAT treatment on a product-by-product basis. Electronic execution of the agreement is valid under the Electronic Transactions and Trust Services Law (Federal Decree-Law No. 46 of 2021).

A Pharmaceutical Supply Agreement in the United Arab Emirates is needed whenever a licensed pharmaceutical distributor enters a commercial supply arrangement with a licensed pharmacy, clinic, hospital, or healthcare group, and both parties need enforceable terms under UAE law.

Public and private hospital procurement is the highest-volume context. Large hospitals across Dubai, Abu Dhabi, and the other emirates maintain formularies of hundreds of medicines and need long-term supply agreements with multiple distributors. The Abu Dhabi Health Services Company (SEHA) and private hospital groups such as Mediclinic Middle East and Cleveland Clinic Abu Dhabi manage pharmaceutical procurement through structured supply agreements that define service levels, pricing compliance with the MOHAP price control framework, stock availability, cold-chain standards, and product recall cooperation.

Community pharmacy chains use pharmaceutical supply agreements with national distributors to ensure uninterrupted stock of prescription and over-the-counter medicines. The DHA, DOH, and MOHAP require licensed pharmacies to source products only from licensed distributors, and a formal supply agreement is the documentation of that licensed supply relationship.

Clinics and medical centres with in-house dispensing require supply agreements for their formulary medicines. As Dubai Healthcare City and Abu Dhabi's healthcare precincts expand, the number of licensed facilities with in-house dispensing rights — and the need for formal supply agreements — grows steadily.

Importers and marketing authorisation holders use pharmaceutical supply agreements to structure their distribution networks across the seven emirates, appointing sub-distributors under framework agreements that define territory, minimum purchase obligations, promotional responsibilities, and MOHAP compliance requirements.

In each context, a written Pharmaceutical Supply Agreement protects both parties by fixing the products, the quality standards, the GDP obligations, the recall procedures, the pricing terms under the MOHAP price control framework, the VAT treatment under the VAT Law (Federal Decree-Law No. 8 of 2017), and the forum for resolving disputes.

A UAE Pharmaceutical Supply Agreement compliant with Federal Law No. 4 of 1983, the UAE Civil Code (Federal Law No. 5 of 1985), and MOHAP Good Distribution Practice standards must contain the following elements. The forms-legal.com UAE Pharmaceutical Supply Agreement template addresses each component in a structure accepted by the Dubai Courts, the Abu Dhabi Judicial Department, and free-zone tribunals.

Party identification must record the full legal name of the supplier and the buyer, the supplier's pharmaceutical wholesale or distribution licence number from MOHAP, DHA, or DOH, the buyer's pharmacy or facility licence number from the relevant authority, and the registered address of each. Both licences must be verified before the agreement is signed.

Product scope must identify the pharmaceutical products covered — by category, formulary schedule, or a reference to purchase orders to be issued under the agreement — and must state that all products supplied must be MOHAP-registered and compliant with UAE pharmaceutical standards. The agreement should address controlled substances separately and confirm compliance with Federal Law No. 14 of 1995.

Delivery and cold-chain requirements must specify delivery timeframes, the address of the buyer's licensed premises, and the temperature and handling requirements for cold-chain products. GDP records — delivery notes, temperature logs, batch certificates — must accompany each delivery.

Pricing and MOHAP price control must address the basis for pricing, the mechanism for applying MOHAP-regulated maximum prices to covered products, the process for price list updates, and the treatment of MOHAP-mandated price changes during the term.

Payment terms must state the payment period in days from delivery and invoice, require valid tax invoices meeting Federal Tax Authority (FTA) requirements, address VAT treatment — distinguishing zero-rated from standard-rated products — and provide for late payment remedies under the Commercial Transactions Law (Federal Decree-Law No. 50 of 2022).

Quality warranties and product recall must include a warranty by the supplier that products are MOHAP-registered, within shelf life, GDP-compliant, and of satisfactory quality. The recall clause must require the supplier to notify the buyer immediately of MOHAP or voluntary recalls and to cooperate in stock retrieval. The buyer must maintain records and cooperate in the recall process.

Regulatory compliance obligations must require both parties to maintain their pharmaceutical licences, comply with MOHAP, DHA, and DOH requirements, permit regulatory inspection of supply records, and notify each other immediately of any licence or compliance issue.

Termination must provide for notice-based termination for convenience, immediate termination on regulatory suspension or revocation of either party's pharmaceutical licence, and termination for material breach drawing on Article 272 of the Civil Code.

Completing a Pharmaceutical Supply Agreement for the United Arab Emirates requires both parties to confirm their pharmaceutical licences and to agree the product scope, pricing, and GDP obligations before filling in the template.

Begin with the parties. Enter the supplier's full legal name as shown on its MOHAP, DHA, or DOH pharmaceutical wholesale or distribution licence. Record the licence number. Enter the buyer's full legal name and its pharmacy or facility licence number from the relevant authority. Record the registered address of each party.

Enter the date of the agreement in DD/MM/YYYY format.

Describe the pharmaceutical products. State whether the agreement covers a fixed formulary or all MOHAP-registered products supplied on purchase orders placed during the term. Where controlled substances are included, note the additional MOHAP permit requirements under Federal Law No. 14 of 1995.

Set the delivery terms. Specify the delivery timeframe from confirmed order, the buyer's licensed delivery address, and the cold-chain requirements for temperature-sensitive products — temperature range, validated packaging, and documentation requirements.

Set the start date and term. State the duration and whether the agreement renews automatically or requires written agreement.

Set the pricing terms. State whether prices are based on the MOHAP price control schedule for regulated products and the supplier's price list for unregulated products. Include a mechanism for automatic adjustment when MOHAP updates regulated prices.

Set the payment terms. Express prices in AED. Clarify VAT treatment for each product category — zero-rated versus standard-rated at 5% under the VAT Law (Federal Decree-Law No. 8 of 2017). Set the payment period and require the supplier to issue compliant tax invoices.

Set the termination notice period and include the immediate termination trigger for MOHAP, DHA, or DOH licence suspension or revocation.

Select the governing courts and arrange signatures. Electronic signatures are valid under the Electronic Transactions and Trust Services Law (Federal Decree-Law No. 46 of 2021). Keep signed copies and delivery records on file.

A Pharmaceutical Supply Agreement in the United Arab Emirates must comply with pharmaceutical-specific regulations on top of the general law of contract.

Federal Law No. 4 of 1983 (the Drug Control Law) is the primary pharmaceutical statute. It establishes the UAE Drug Register and makes it unlawful to import, manufacture, distribute, or dispense a pharmaceutical product unless it is registered with MOHAP. It requires distributors and pharmacies to hold the appropriate licences from MOHAP, DHA, or DOH and sets out the penalties for supply of unregistered or substandard products.

Federal Law No. 14 of 1995 on the Countermeasures Against Narcotic Drugs and Psychotropic Substances governs the supply of controlled substances. Additional MOHAP permits are required for each import, export, and supply transaction involving controlled substances, and quantities must be accounted for precisely.

Good Distribution Practice standards issued by MOHAP, based on the WHO GDP model, require the entire distribution chain to maintain temperature integrity, batch traceability, and documentation sufficient to enable full product recall. Non-compliance with GDP is a basis for MOHAP sanction, including suspension of the distribution licence.

The UAE Civil Code (Federal Law No. 5 of 1985) governs the contractual relationship: Article 125 on formation, Article 246 on good-faith performance, Articles 282 and 389 on compensation for breach. The Commercial Transactions Law (Federal Decree-Law No. 50 of 2022) governs commercial supply obligations between merchant parties. The VAT Law (Federal Decree-Law No. 8 of 2017) determines tax treatment: zero-rating under Cabinet Decision No. 52 of 2017 for qualifying medicines, standard rate of 5% for others. The Electronic Transactions and Trust Services Law (Federal Decree-Law No. 46 of 2021) validates electronic execution.

A UAE Pharmaceutical Supply Agreement involves one of the most regulated commercial activities in the country. The following errors create regulatory exposure or commercial disputes.

1. Not verifying the other party's pharmaceutical licence before signing. A buyer that contracts with a supplier whose MOHAP, DHA, or DOH distribution licence does not cover the products being supplied risks receiving unregulated stock. A supplier that supplies to a buyer without a valid pharmacy or facility licence risks MOHAP sanctions. Verify both licences on the relevant health authority's register before execution.

2. No MOHAP product registration requirement. An agreement that does not require all supplied products to be registered on the UAE Drug Register leaves open the risk of the supplier substituting unregistered or grey-market products. State expressly that only UAE Drug Register products may be supplied.

3. Omitting cold-chain documentation requirements. For temperature-sensitive products, omitting GDP documentation requirements — temperature logs, delivery records, validated packaging specs — removes the buyer's ability to demonstrate supply chain integrity to DHA, DOH, or MOHAP inspectors and voids any product liability claim against the supplier for temperature excursions.

4. Inadequate product recall clause. A recall clause that merely requires the supplier to notify the buyer of a recall, without specifying timeframes, requiring batch traceability records, or imposing stock retrieval obligations, is unenforceable in practice. Recall obligations must be specific and immediate.

5. Ignoring MOHAP price control. Setting supply prices above the MOHAP-regulated maximum for controlled products constitutes a breach of UAE pharmaceutical regulations. The pricing clause must acknowledge and comply with the MOHAP price control framework.

6. Incorrect VAT treatment. Applying zero-rating to products not on the Cabinet Decision No. 52 of 2017 schedule, or failing to charge VAT on standard-rated pharmaceutical products, can result in FTA penalties and retrospective VAT assessments.

7. No immediate termination right on licence revocation. Without an automatic right to terminate on MOHAP, DHA, or DOH licence suspension, the buyer may be obligated to continue purchasing from a supplier that can no longer lawfully supply pharmaceutical products, exposing the buyer to regulatory risk.